- Home
- RRGB vs PRLD Comparison
RRGB vs PRLD Comparison
Compare RRGB & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RRGB | PRLD |
|---|---|---|
| Founded | 1969 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.4M | 69.1M |
| IPO Year | 2002 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RRGB | PRLD |
|---|---|---|
| Price | $4.00 | $2.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $9.67 | $4.00 |
| AVG Volume (30 Days) | 162.9K | ★ 605.6K |
| Earning Date | 02-25-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,226,409,000.00 | $10,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 250.00 |
| 52 Week Low | $2.50 | $0.61 |
| 52 Week High | $7.89 | $4.22 |
Technical Indicators
Market Signals| Indicator | RRGB | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 41.42 | 48.71 |
| Support Level | $3.98 | $2.37 |
| Resistance Level | $4.18 | $2.99 |
| Average True Range (ATR) | 0.16 | 0.30 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 10.17 | 16.84 |
Price Performance
Historical ComparisonAbout RRGB Red Robin Gourmet Burgers Inc.
Red Robin Gourmet Burgers Inc is a restaurant operator. The company develops, operates, and franchises casual-dining restaurants and fast-casual restaurants in North America. Its brands are Red Robin, Red Robin Gourmet Burgers, Red Robin America's Gourmet Burgers and Spirits, Red Robin Burger Works, YUMMM, Red Robin Gourmet Burgers and Brews, and Red Robin Royalty names and logos. The company's revenue consists of sales from restaurant operations, gift card breakage, franchise royalties and fees, and other miscellaneous revenue. The company has one operating and one reportable segment: restaurants.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.